Analyzing Harrow (NASDAQ:HROW) & Silo Pharma (NASDAQ:SILO)

Silo Pharma (NASDAQ:SILO – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Institutional and Insider Ownership

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Silo Pharma has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.

Earnings & Valuation

This table compares Silo Pharma and Harrow”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silo Pharma $54,077.00 46.25 -$4.23 million ($2.77) -0.57
Harrow $303.25 million 3.60 -$5.14 million ($0.78) -37.29

Silo Pharma has higher earnings, but lower revenue than Harrow. Harrow is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Silo Pharma and Harrow’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Silo Pharma -6,726.39% -66.16% -54.26%
Harrow -9.39% -69.81% -5.16%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Silo Pharma and Harrow, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silo Pharma 1 0 0 0 1.00
Harrow 2 1 6 0 2.44

Harrow has a consensus target price of $66.20, indicating a potential upside of 127.57%. Given Harrow’s stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than Silo Pharma.

Summary

Harrow beats Silo Pharma on 9 of the 14 factors compared between the two stocks.

About Silo Pharma

(Get Free Report)

Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on treatments for central nervous system disorders and pain conditions. Its research programs include potential therapies for post-traumatic stress disorder, Alzheimer’s disease and chronic pain. The company works on drug candidates and delivery approaches involving compounds such as ketamine, including formulations intended to support targeted or sustained treatment. Silo’s programs remain in development, and the company does not have a marketed product.

About Harrow

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.